Vaidya Sane Ayurved Laboratories Ltd
Vaidya Sane Ayurved Laboratories Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Targeting over 12,000 to 13,000 new patients per month soon, up from 8,000-9,000 currently, indicating growth in patient footfall and sales. Revenue for next year (FY'26) is expected around Rs.
From Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Targeting over 12,000 to 13,000 new patients per month soon, up from 8,000-9,000 currently, indicating growth in patient footfall and sales.
- Planning to add 30 new clinics in FY'26 across multiple states (Gujarat, Madhya Pradesh, Karnataka, Maharashtra) to expand reach.
- Hospital bed capacity to increase with additional beds at Khopoli, Nagpur, and Gujarat hospitals, including scaling Vadodara hospital from 20 to 100 beds in 12-15 months.
- Expected revenue growth of around 20% year-on-year, with monthly revenues scaling from Rs.7 crore in April 2025.
- Enrollment ratio improving, leading to increased care plan sales despite a dip in new patient footfall last year.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vaidya Sane Ayurved Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Permission secured for construction of 100 additional beds at Khopoli hospital.
- Nagpur hospital approved for 50% expansion adding 20 to 40 beds within the year.
- Vadodara hospital plans to expand from 30 to about 90-100 beds.
- Total targeted bed addition for FY'26 is approximately 200 beds.
- New clinic expansion planned with 30 additional clinics across Gujarat, Madhya Pradesh, Karnataka, and Maharashtra.
- Aggressive hospital network expansion including plans for over 1,000 beds and clinics by 2030, focusing on tier 1 and 2 cities in India.
- Institute of Preventive Cardiology aims to train over 10,000 physicians to support growth.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vaidya Sane Ayurved Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders.
- However, strategic focus is on expanding clinic network and hospital infrastructure, aiming for about 1,000 clinics and 1,000+ beds by 2030.
- New patient footfall targets are increasing from 9,000 to 12,000-13,000 per month, indicating growing demand.
- Planned addition of approximately 30 new clinics in FY'26.
- Hospital bed expansion plans: 100 more beds in Khopoli, 20-40 beds in Nagpur, and 60-70 beds in Vadodara expected within fiscal year 2026.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Vaidya Sane's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Poly Medicure Ltd (Q4 FY25)
EBITDA margins guided between 25%-27%, with potential upside if export growth exceeds 15%. Key concall takeaways from Poly Medicure Ltd's Q4 FY25 earnings call…
- OSEL Devices (Q4 FY25)
Current order-in-hand for OSEL Devices Limited is approximately INR 40-45 crores. Key concall takeaways from OSEL Devices Ltd's Q4 FY25 earnings call — and how…
- Prevest Denpro (Q4 FY25)
The management emphasizes growth in both domestic and export markets, indicating healthy order inflows aligned with a 13% sales increase in FY25. Key concall…
- Aprameya Enginee (Q4 FY25)
Current order book: Approximately INR 60 crores. Key concall takeaways from Aprameya Engineering Ltd's Q4 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Vaidya Sane Ayurved Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vaidya Sane Ayurved Laboratories Ltd Q4 FY25 results?
Targeting over 12,000 to 13,000 new patients per month soon, up from 8,000-9,000 currently, indicating growth in patient footfall and sales. Revenue for next year (FY'26) is expected around Rs.
What is Vaidya Sane Ayurved Laboratories Ltd share price analysis?
Vaidya Sane Ayurved Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 22.4 with a market cap of ₹202 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vaidya Sane Ayurved Laboratories Ltd planning capital expenditure?
Permission secured for construction of 100 additional beds at Khopoli hospital.
Keep Vaidya Sane Ayurved Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.